Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

ns.  Sales increased in the quarter despite the decline in TriCor/Trilipix sales due to the loss of exclusivity.  Excluding TriCor/Trilipix sales and foreign exchange, sales increased 10.9 percent in the quarter.  
  • Sales growth was driven by the continued strength of HUMIRA.  Global HUMIRA sales increased 19.1 percent on both a reported and operational basis.  U.S. HUMIRA sales grew 22.3 percent.  Total company sales growth was also driven by strong growth from other products including Synthroid, Creon, Zemplar and Duodopa.
  • Third-quarter adjusted gross margin ratio was 79.7 percent, excluding intangible asset amortization and other specified items.  Gross margin strength in the quarter was driven by operational efficiencies and product mix, including strong HUMIRA sales and better-than-expected lipid performance despite loss of exclusivity.  The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 76.6 percent.  
  • Adjusted selling, general and administrative (SG&A) expense was 26.1 percent of sales in the third quarter, reflecting continued investment in our growth brands.  On a GAAP basis, SG&A was 27.1 percent of sales.
  • Adjusted research and development (R&D) was 15.2 percent of sales in the quarter, reflecting funding actions in support of our emerging mid- and late-stage pipeline assets and the continued pursuit of additional HUMIRA indications.  On a GAAP basis, R&D was 15.3 percent of sales.
  • Net interest expense was $69 million, and the adjusted tax rate was 22.3 percent in the quarter.  On a GAAP basis, the third-quarter tax rate was 25.0 percent.
  • Third-quarter diluted earnings per share were $0.60 on a GAAP basis.  Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $0.82, above the company's previous guidance range.  

  • '/>"/>
    SOURCE AbbVie
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. AbbVie Named a Science Top Employer
    2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
    6. AbbVie Declares Quarterly Dividend
    7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
    9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
    10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
    11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) today announced ... transaction on Tuesday to help fund the expansion and consolidation ... Sharon . PHN is ... Pennsylvania . It is the largest employer in ... 150 people on staff. Currently, PHN Sharon offers ...
    (Date:12/24/2014)... 2014 Kinex Pharmaceuticals announced today that the ... Park Cancer Institute. KX2-361 (KX02), a dual ... shown potent inhibitory activity against a broad panel of ... to Temozolomide (T98G), the most widely used chemotherapy for ... tumor mouse model, KX2-361 consistently clears brain tumors after ...
    (Date:12/24/2014)... 2014  The International Trade Commission (ITC) issued its final ... Medical. In a notice issued on December 23, the ITC ... on its humidifier was invalid. BMC President, ... are very excited with the ITC,s decision in this case. ... taken since the very beginning on the key patents in ...
    Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
    (Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
    (Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
    (Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
    (Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
    (Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
    ... , THURSDAY, Sept. 15 (HealthDay News) -- Fruits and vegetables ... stroke more than other fruits and vegetables, Dutch researchers report. ... vegetables consumed led to a 9 percent decrease in the ... commonly consumed "white fruit," according to the study, published in ...
    ... children admitted to hospitals or seen in emergency departments ... medication has risen dramatically in recent years, according to ... The rise in exposure to prescription products ... Control and Prevention has established the PROTECT Initiative, intended ...
    ... -- The facts about cancer found on the website ... the disease found on the patient-oriented section of the ... comprehensive peer-reviewed cancer database, according to a new study. ... hard-pressed to find errors on Wikipedia, they did find ...
    ... Glioblastoma is among the most lethal cancers, but ... patients with glioblastoma could be treated with cholesterol-lowering agents, ... newest journal of the American Association for Cancer Research. ... Harrison Latta professor of pathology and laboratory medicine, and ...
    ... promising new therapies for ependymoma, a rare tumor ... Hospital investigators led the effort, which used a ... latest drug screening technology with the first accurate ... several dozen new and existing drugs as possible ...
    ... 15, 2011 The demand for transparency through publicly available ... for administrative and clinical data for research, and for clinical ... access has a measurable impact on research and policy making. ... Research Chair in Electronic Health Information at the University of ...
    Cached Medicine News:Health News:An Apple a Day Really May Keep the Doctor Away 2Health News:An Apple a Day Really May Keep the Doctor Away 3Health News:Number of children poisoned by medication rising dramatically, study says 2Health News:Wikipedia Accurate on Cancer Facts, But Hard to Read: Study 2Health News:Targeting cholesterol may help slow glioblastoma 2Health News:New strategy likely to speed drug development for rare cancers 2Health News:New strategy likely to speed drug development for rare cancers 3Health News:New report on creating clinical public use microdata files 2
    ... and CVA for CELL-DYN are assayed linearity ... calibration and to verify patient reportable range ... kits also measure the linear performance of ... kits have customized ranges appropriate for each ...
    ... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
    ... negative whole blood control to test for ... tests and hemoglobin electrophoresis. Sickle-Chex is compatible ... solubility kits. Sickle-Chex is packaged in a ... dispenses an accurate sample volume. No pipeting ...
    ... Proprietary EX.P.R.T. Release Technology ... No stent shortening,, Unique anatomically designed ... the carotid bifurcation,, 0.014 Rapid Exchange ... profile and flexible atraumatic tip,, Radiopaque ...
    Medicine Products: